MV
MedImmune Ventures
Corporate VCActiveMedImmune Ventures invests in early to late stage, public and private biotechnology companies.
45
Investments
2
Exits
—
AUM
4.4%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for MedImmune Ventures.
Investment Thesis & Strategy
MedImmune Ventures invests in early to late-stage biotechnology companies, both public and private, leveraging its expertise in the biotech industry.
Notable Exits
CompanyTypeYearValue / Acquirer
MedivationAcquisition2016$14B
Alvine PharmaceuticalsAcquisition2013—
Frequently Asked Questions
MedImmune Ventures focuses on Series A, Series B stage investments.